A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19)
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003149
- Lead Sponsor
- Hospital of Chengdu University of Traditional Chinese Medicine.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. During the outbreak of new coronavirus pneumonia, patients with fever caused by respiratory infection (body temperature > 37 degree C), whether or not they are suspected or confirmed cases of new coronary pneumonia;
2. Comply with the diagnostic criteria of TCM for wind-heat and dampness or wind-cold and dampness syndrome;
3. Aged 18 to 75 years;
4. Outpatients or inpatients admitted by second-level and above medical institutions;
5. Voluntarily joined the study, with good compliance and signed informed consent.
1. Known allergies to the components of this study;
2. Non-fever non-new coronary pneumonia diagnosed or suspected;
3. Fever caused by other non-infectious causes;
4. Patients with tuberculosis, bronchial asthma, chronic obstructive pulmonary disease, and respiratory failure;
5. Patients who are unwilling to take traditional Chinese medicine preparations;
6. Women during pregnancy and lactation who have fertility requirements in the last 3 months;
7. Participating in clinical trials of other drugs;
8. Other reasons led the researchers to consider it inappropriate to participate in this study.
Study & Design
- Study Type
- Treatment study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body temperature returns to normal time;After the medication, the disappearance rate of TCM symptoms;
- Secondary Outcome Measures
Name Time Method